People: Mannkind Corp (MNKD.W)

Summary

Name	Age	Since	Current Position
Alfred Mann	87	2003	Chairman of the Board, Chief Executive Officer
Hakan Edstrom	63	2001	President, Chief Operating Officer, Director
Matthew Pfeffer	55	2008	Corporate Vice President and Chief Financial Officer
Juergen Martens	57	2005	Corporate Vice President - Technical Operations, Chief Technical Officer
David Thomson	46	2002	Corporate Vice President, General Counsel and Corporate Secretary
Diane Palumbo	59	2004	Corporate Vice President - Human Resources
Ronald Consiglio	68	2003	Independent Director
Michael Friedman	69	2003	Independent Director
Kent Kresa	74	2004	Independent Director
David MacCallum	74	2004	Independent Director
Henry Nordhoff	70	2005	Independent Director

» Insider Trading

Biographies

Name	Description
Alfred Mann	Mr. Alfred E. Mann is Chairman of the Board, Chief Executive Officer of MannKind Corpoartion. He founded and formerly served as Chairman and Chief Executive Officer of MiniMed, Inc., a publicly traded company focused on diabetes therapy and microinfusion drug delivery that was acquired by Medtronic, Inc. in August 2001. Mr. Mann also founded and, from 1972 through 1992, served as Chief Executive Officer of Pacesetter Systems, Inc. and its successor, Siemens Pacesetter, Inc., a manufacturer of cardiac pacemakers, now the Cardiac Rhythm Management Division of St. Jude Medical Corporation. Mr. Mann founded and since 1993, has served as Chairman and until January 2008, as Co-Chief Executive Officer of Advanced Bionics Corporation, a medical device manufacturer focused on neurostimulation to restore hearing to the deaf and to treat chronic pain and other neural deficits, that was acquired by Boston Scientific Corporation in June 2004. In January 2008, the former stockholders of Advanced Bionics Corporation repurchased certain segments from Boston Scientific Corporation and formed Advanced Bionics LLC for cochlear implants and Infusion Systems LLC for infusion pumps. Mr. Mann is the managing member of the Alfred Mann Foundation and is also non-executive Chairman of Alfred Mann Institutes at the University of Southern California, AMI Purdue and AMI Technion, and the Alfred Mann Foundation for Biomedical Engineering, which is establishing additional institutes at other research universities. Mr. Mann holds bachelor’s and master’s degrees in Physics from the University of California at Los Angeles, honorary doctorates from Johns Hopkins University, the University of Southern California, Western University and the Technion-Israel Institute of Technology and is a member of the National Academy of Engineering.
Hakan Edstrom	Mr. Hakan S. Edstrom is President, Chief Operating Officer, Director of MannKind Corporation. He has been President and Chief Operating Officer since April 2001 and has served as one of the Directors since December 2001. Mr. Edstrom was with Bausch & Lomb, Inc., a health care product company, from January 1998 to April 2001, advancing to the position of Senior Corporate Vice President and President of Bausch & Lomb, Inc. Americas Region. From 1981 to 1997, Mr. Edstrom was with Pharmacia Corporation, where he held various executive positions, including President and Chief Executive Officer of Pharmacia Ophthalmics Inc. Mr. Edstrom is currently a director of Q-Med AB, a biotechnology and medical device company. Mr. Edstrom was educated in Sweden and holds a master’s degree in business administration from the Stockholm School of Economics.
Matthew Pfeffer	Mr. Matthew J. Pfeffer is Chief Financial Officer, Corporate Vice President of MannKind Corporation. Previously, Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008, with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer serves on boards and advisory committees of the Biotechnology Industry Organization and the American Institute of Certified Public Accountants. Mr. Pfeffer has a bachelor’s degree in Accounting from the University of California, Berkeley and is a Certified Public Accountant.
Juergen Martens	Dr. Juergen A. Martens, Ph.D., is Corporate Vice President - Technical Operations, Chief Technical Officer of MannKind Corporation. From 2000 to August 2005, he was employed by Nektar Therapeutics, Inc., most recently as Vice President of Pharmaceutical Technology Development. Previously, he held technical management positions at Aerojet Chemicals from 1998 to 2000 and at FMC Corporation from 1996 to 1998. From 1987 to 1996, Dr. Martens held a variety of management positions with increased responsibility in R&D, plant management, and business process development at Lonza, in Switzerland and in the United States. Dr. Martens holds a bachelor’s degree in chemical engineering from the Technical College Mannheim/Germany, a bachelor’s and master’s degree in Chemistry and a doctorate in Physical Chemistry from the University of Marburg/Germany.
David Thomson	Dr. David B. Thomson, Ph.D., J.D., is Corporate Vice President, General Counsel, Corporate Secretary of MannKind Corporation. Prior to joining the company, he practiced corporate/commercial and securities law at a Toronto law firm. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. degree from Queens University and obtained his J.D. degree from the University of Toronto.
Diane Palumbo	Ms. Diane M. Palumbo is Corporate Vice President - Human Resources of MannKind Corporation. From July 2003 to November 2004, she was President of her own human resources consulting company. From June 1991 to July 2003, Ms. Palumbo held various positions with Amgen, Inc., a California-based biopharmaceutical company, including Senior Director, Human Resources. In addition, Ms. Palumbo has held Human Resources positions with Unisys and Mitsui Bank Ltd. of Tokyo. She holds a master’s degree in Business Administration from St. John’s University, New York and a bachelor’s degree, magna cum laude, also from St. John’s University.
Ronald Consiglio	Mr. Ronald Consiglio serves as an Independent Director of Mannkind Corporation since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio is currently a member of the board of trustees for the Metropolitan West Funds. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge.
Michael Friedman	Dr. Michael A. Friedman, M.D., serves as an Independent Director of MannKind Corporation since December 2003. Currently, Dr. Friedman is the President and Chief Executive Officer of the City of Hope National Medical Center. Previously, from September 2001 until April 2003, Dr. Friedman held the position of Senior Vice President of Research and Development, Medical and Public Policy, for Pharmacia Corporation and, from July 1999 until September 2001, was a senior vice president of Searle, a subsidiary of Monsanto Company. From 1995 until June 1999, Dr. Friedman served as Deputy Commissioner for Operations for the Food and Drug Administration, and was Acting Commissioner and Lead Deputy Commissioner from 1997 to 1998. Dr. Friedman received a bachelor of arts degree, magna cum laude, from Tulane University, New Orleans, Louisiana, and a doctorate in medicine from the University of Texas, Southwestern Medical School.
Kent Kresa	Mr. Kent Kresa serves as an Independent Director of Mannkind Corporation since June 2004. Mr. Kresa is Chairman Emeritus of Northrop Grumman Corporation, a defense company and from September 1990 until October 2003, he was its Chairman. He also served as Chief Executive Officer of Northrop Grumman Corporation from January 1990 until March 2003 and as its President from 1987 until September 2001. Mr. Kresa is also Chairman of the Board of Trustees of the California Institute of Technology (“Caltech”) and has been a member of the Caltech Board of Trustees since 1994. Mr. Kresa serves on the boards of Fluor Corporation, and several non-profit organizations and universities. He is also on the Advisory Board of Trust Company of the West. As a graduate of Massachusetts Institute of Technology, he received a B.S. in 1959, an M.S. in 1961, and an E.A.A. in 1966, all in aeronautics and astronautics.
David MacCallum	Mr. David H. MacCallum serves as an Independent Director of MannKind Corporation since June 2004. Currently, Mr. MacCallum is the Managing Partner of Outer Islands Capital, a hedge fund specializing in health care investments. From June 1999 until November 2001, he was Global Head of Health Care investment banking for Salomon Smith Barney, part of Citigroup, a financial institution. Prior to joining Salomon Smith Barney, he was Executive Vice President and Head of the Health Care group at ING Barings Furman Selz LLC, an investment banking firm and subsidiary of ING Group, a Dutch financial institution, from April 1998 to June 1999. Prior to that, Mr. MacCallum formed the Life Sciences group at UBS Securities, an investment banking firm, where he was Managing Director and Global Head of Life Sciences from May 1994 to April 1998. Before joining UBS Securities, he built the health care practice at Hambrecht & Quist, an investment banking firm, where he was Head of Health Care and Co-Head of Investment Banking. Mr. MacCallum received an A. B. degree from Brown University and an M.B.A. degree from New York University. He is a Chartered Financial Analyst.
Henry Nordhoff	Mr. Henry L. Nordhoff serves as an Independent Director of MannKind Corporation since March 2005. Mr. Nordhoff has served as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, since September 2002 and served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University.

Basic Compensation

Name	Fiscal Year Total
Alfred Mann	2,667,040
Hakan Edstrom	2,406,820
Matthew Pfeffer	911,707
Juergen Martens	1,038,660
David Thomson	852,073
Diane Palumbo	892,392
Ronald Consiglio	--
Michael Friedman	--
Kent Kresa	--
David MacCallum	--
Henry Nordhoff	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Alfred Mann	340,972	0
Hakan Edstrom	801,411	4,068,343
Matthew Pfeffer	6,300	44,982
Juergen Martens	0	0
David Thomson	228,796	1,527,877
Diane Palumbo	0	0
Ronald Consiglio	0	0
Michael Friedman	0	0
Kent Kresa	0	0
David MacCallum	0	0
Henry Nordhoff	0	0

Insider Trading

Name	Shares Traded	Price
MARTENS JUERGEN A	3,050	$2.62
EDSTROM HAKAN S	9,922	$2.62
THOMSON DAVID	3,401	$2.62
PALUMBO DIANE M	3,401	$2.62
MARTENS JUERGEN A	3,050	$2.62
PFEFFER MATTHEW J	1,056	$1.95
MANN ALFRED E	2,398,126	$0.00
MANN ALFRED E	800,000	$0.00
MANN ALFRED E	14,999,910	$0.00
MANN ALFRED E	1,305,000	$0.00
MANN ALFRED E	2,000,000	$0.00
MANN ALFRED E	40,000,000	$2.59
MANN ALFRED E	10,601,784	$0.00
PALUMBO DIANE M	1,101	$2.35
THOMSON DAVID	1,193	$2.35
EDSTROM HAKAN S	3,916	$2.35
EDSTROM HAKAN S	3,485	$2.35
THOMSON DAVID	1,101	$2.35
MARTENS JUERGEN A	995	$2.35
PALUMBO DIANE M	1,193	$2.35
MARTENS JUERGEN A	1,219	$2.35
MARTENS JUERGEN A	1,575	$2.35
THOMSON DAVID	1,514	$2.35
EDSTROM HAKAN S	6,970	$2.35
PALUMBO DIANE M	1,514	$2.35

» Full list on Insider Trading

People: Mannkind Corp (MNKD.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: